|
1
|
Abduh MS: An overview of multiple myeloma:
A monoclonal plasma cell malignancy's diagnosis, management, and
treatment modalities. Saudi J Biol Sci. 31(103920)2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Forster S, Radpour R and Ochsenbein AF:
Molecular and immunological mechanisms of clonal evolution in
multiple myeloma. Front Immunol. 14(1243997)2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Giannakoulas N, Ntanasis-Stathopoulos I
and Terpos E: The role of marrow microenvironment in the growth and
development of malignant plasma cells in multiple myeloma. Int J
Mol Sci. 22(4462)2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wang L, Shi M, Sung AY, Yin CC, Bai Y and
Chen M: Role of the bone marrow microenvironment in multiple
myeloma: Impact of niches on drug resistance mechanisms. Semin
Diagn Pathol. 42(150916)2025.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Pinto V, Bergantim R, Caires HR, Seca H,
Guimarães JE and Vasconcelos MH: Multiple myeloma: Available
therapies and causes of drug resistance. Cancers (Basel).
12(407)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Nass J and Efferth T: Drug targets and
resistance mechanisms in multiple myeloma. Cancer Drug Resist.
1:87–117. 2018.
|
|
7
|
Corre J, Munshi NC and Avet-Loiseau H:
Risk factors in multiple myeloma: Is it time for a revision? Blood.
137:16–19. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wallington-Beddoe CT and Mynott RL:
Prognostic and predictive biomarker developments in multiple
myeloma. J Hematol Oncol. 14(151)2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hanbali A, Hassanein M, Rasheed W, Aljurf
M and Alsharif F: The evolution of prognostic factors in multiple
myeloma. Adv Hematol. 2017(4812637)2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Greipp PR, San Miguel J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H,
Kyle RA, et al: International staging system for multiple myeloma.
J Clin Oncol. 23:3412–3420. 2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Romano A, Laura Parrinello N, Cerchione C,
Letizia Consoli M, Parisi M, Calafiore V, Martino E, Conticello C,
Di Raimondo F and Alberto Palumbo G: The NLR and LMR ratio in newly
diagnosed MM patients treated upfront with novel agents. Blood
Cancer Journal. 7(649)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kaddoura M, Binder M, Dingli D, Buadi FK,
Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa L, Fonder A, et al:
Impact of achieving a complete response to initial therapy of
multiple myeloma and predictors of subsequent outcome. Am J
Hematol. 97:267–273. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Palumbo A, Avet-Loiseau H, Oliva S,
Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S,
Lahuerta JJ, Facon T, et al: Revised international staging system
for multiple myeloma: A report from international myeloma working
group. J Clin Oncol. 33:2863–2869. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Rajkumar SV: Multiple myeloma: 2024 update
on diagnosis, risk-stratification, and management. Am J Hematol.
99:1802–1824. 2024.PubMed/NCBI View Article : Google Scholar
|
|
15
|
D'Agostino M, Cairns DA, Lahuerta JJ,
Wester R, Bertsch U, Waage A, Zamagni E, Mateos MV, Dall'Olio D,
van de Donk NWCJ, et al: Second revision of the international
staging system (R2-ISS) for overall survival in multiple myeloma: A
European myeloma network (EMN) report within the HARMONY project. J
Clin Oncol. 40:3406–3418. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kelkitli E, Atay H, Cilingir F, Güler N,
Terzi Y, Ozatlı D and Turgut M: Predicting survival for multiple
myeloma patients using baseline neutrophil/lymphocyte ratio. Ann
Hematol. 93:841–846. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wongrakpanich S, George G, Chaiwatcharayut
W, Biso S, Candelario N, Mittal V, Pomerantz S and Varadi G: The
prognostic significance of neutrophil-to-lymphocyte and
platelet-to-lymphocyte ratios in patients with multiple myeloma. J
Clin Lab Anal. 30:1208–1213. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Onec B, Okutan H, Albayrak M, Saribacak
Can E, Aslan V, Unver Koluman B, Soyer Kosemehmetoglu O, Albayrak A
and Kos DM: The Predictive role of the neutrophil/lymphocyte ratio
in survival with multiple myeloma: A single center experience. J
Clin Lab Anal. 31(e22032)2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mu S, Ai L, Fan F, Sun C and Hu Y:
Prognostic role of neutrophil-lymphocyte ratio in multiple myeloma:
A dose-response meta-analysis. Onco Targets Ther. 11:499–507.
2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zeng Q, Liu Z, Li Q and Liu T: Prognostic
value of neutrophil to lymphocyte ratio and clinicopathological
characteristics for multiple myeloma: A meta-analysis. Medicine
(Baltimore). 97(e12678)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Szudy-Szczyrek A, Mlak R, Mielnik M,
Szczyrek M, Nowaczyńska A, Homa-Mlak I, Zmorzyński S, Kuśmierczuk
K, Sompor J, Filip A, et al: Prognostic value of pretreatment
neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in
multiple myeloma patients treated with thalidomide-based regimen.
Ann Hematol. 99:2881–2891. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhang X, Duan J, Wen Z, Xiong H, Chen X,
Liu Y, Liao K and Huang C: Are the derived indexes of peripheral
whole blood cell counts (NLR, PLR, LMR/MLR) clinically significant
prognostic biomarkers in multiple myeloma? A systematic review and
meta-analysis. Front Oncol. 11(766672)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Giri S, Dahal S, Bal S, Godby KN, Richman
J, Olszewski AJ, Williams GR, Brown C, Buford TW, Costa LJ and
Bhatia S: Pre-treatment neutrophil to lymphocyte ratio as a
biomarker of frailty and predictor of survival among older adults
with multiple myeloma. J Geriatr Oncol. 13:486–492. 2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mikulski D, Kościelny K, Nowicki M,
Wawrzyniak E, Kalwas M, Kowalik M, Pryt M, Sęczkowska E, Świątek A,
Wierzbowska A and Fendler W: Neutrophil to lymphocyte ratio (NLR)
impact on the progression-free survival and overall survival of
multiple myeloma patients treated with high-dose chemotherapy and
autologous stem cell transplantation. Leuk Lymphoma. 64:98–106.
2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Mehra K, Ramasamy C, Perkit NR, Singh A,
Kumar MS and Seetharaman K: Significance of
neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and
monocyte-to-lymphocyte ratio in the prognosis of newly diagnosed
multiple myeloma patients. Blood. 142 (Suppl 1)(S6695)2023.
|
|
26
|
Zhang Y, Yao X, Zhang Y, Chen Z, Qin Z,
Cai Y, Xia W and Hu H: Albumin-to-globulin ratio combined with
neutrophil-to-lymphocyte ratio as a prognostic predictor in
multiple myeloma with renal impairment. Blood Lymphat Cancer.
14:49–62. 2024.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang M, Yue X, Ding Y, Cai Z, Xiao H,
Huang H and He J: A nomogram based on circulating inflammatory
factors for predicting prognosis of newly diagnosed multiple
myeloma patients. J Inflamm Res. 18:2077–2090. 2025.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Abdallah NH, Smith AN, Geyer S, Binder M,
Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ,
et al: Conditional survival in multiple myeloma and impact of
prognostic factors over time. Blood Cancer J. 13(78)2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kumar S, Leleu X, Weisel K, Popat R,
Craigie S, Patel L, Ramirez AO, Ge W, MA Q, Hampp C and Jagannath
S: PB2090: Systematic literature review of prognostic factors for
relapsed/refractory multiple myeloma. Hemasphere. 7
(Suppl)(e9426734)2023.
|
|
30
|
Ferri GM, Yildirim C, Park J, Do VN,
Brophy MT, Munshi NC, Fillmore NR and Edwards CV: Development of
novel peripheral blood count-based prognostic index for multiple
myeloma. Blood. 144 (Suppl 1)(S6981)2024.
|
|
31
|
Kumar S, Leleu X, Weisel KC, Popat R,
Suero B, Craigie S, Spin P, Patel L, Ramirez AO, Hampp C, et al:
Ranking the importance of prognostic factors for
relapsed/refractory multiple myeloma: international physician panel
consensus following a systematic literature review. Clin Lymphoma
Myeloma Leuk. 25:730–738.e11. 2025.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhou X, Wang J, Xia J, Cheng F, Mao J, Zhu
J and Guo H: Evaluation of neutrophil-to-lymphocyte ratio in newly
diagnosed patients receiving borte-zomib-based therapy for multiple
myeloma. Cancer Biomark. 22:43–48. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Avagyan G, Voskanyan A, Grigoryan A,
Saaryan M, Muradyn L, Avagyan G and Ghahramanyan N: MM-469 The
prognostic value of serum calcium levels, neutrophil to lymphocyte
ratio and platelet count in multiple myeloma: A retrospective
cohort study. Clin Lymphoma Myeloma Leuk. 24 (Suppl
1)(S559)2024.
|
|
34
|
Azam F, Latif MF, Farooq A, Tirmazy SH,
AlShahrani S, Bashir S and Bukhari V: Performance status assessment
by using ECOG (eastern cooperative oncology group) score for cancer
patients by oncology healthcare professionals. Case Rep Oncol.
12:728–736. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Garderet L, D'Souza A, Jacobs P, van
Biezen A, Schönland S, Kroeger N, Morris C and Hari P: Response
assessment in myeloma: Practical manual on consistent reporting in
an era of dramatic therapeutic advances. Biol Blood Marrow
Transplant. 23:1193–1202. 2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Liu S, Shi J, Guo H, Xu F, Wei M, Sun K
and Chen Y: Prognostic significance of the inflammatory index-based
scoring system in patients preliminarily diagnosed with multiple
myeloma in the bortezomib-based chemotherapy era. Cancer Manag Res.
11:9409–9420. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kalal AA, Shetty VV, Shetty KP, Arumugam
M, Shetty RA, Kulkarni NV and Shetty DP: Correlation between
platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio
with hematological parameters in multiple myeloma patients. Biomed
Biotechnol Res J. 6:132–137. 2022.
|
|
38
|
Zhaoyun L and Rong F: Predictive role of
immune profiling for survival of multiple myeloma patients. Front
Immunol. 12(663748)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Diaconescu D, Ilinescu AM, Popescu CD,
Soare DB, Ene G and Bumbea H: Prognostic significance of neutrophil
to lymphocyte ratio in multiple myeloma patient. Doc Haematol Rev
Rom Hematol. 3:81–87. 2025.
|
|
40
|
LeBlanc R, Bergstrom DJ, Côté J, Kotb R,
Louzada ML and Sutherland HJ: Management of myeloma manifestations
and complications: The cornerstone of supportive care:
Recommendation of the Canadian myeloma research group (formerly
myeloma Canada research network) consensus guideline consortium.
Clin Lymphoma Myeloma Leuk. 22:e41–e56. 2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zuo H, Zhai L, Liu X, Gao H and Xu P:
Prognostic significance of neutrophil-lymphocyte ratio in multiple
myeloma patients. Transl Cancer Res. 7:88–96. 2018.
|
